ROCKVILLE, Md., June 26, 2007 — Cytomedix, Inc. today announced that the Centers for Medicare and medicaid services has agreed to Cytomedix’s request to reconsider a non-coverage decision for autologous blood-derived products when used for the treatment of chronic non-healing wounds.

Read more here…